Is TxCell close to delivering affordable personalised therapies for chronic autoimmune inflammatory diseases?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Is TxCell close to delivering affordable personalised therapies for chronic autoimmune inflammatory diseases?
Released on: August 21, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    TxCell is developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases.
  • Summary
  • Transcript
  • Participants
  • Company
TxCell is developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases. PharmaVentures' Adrian Dawkes asks Damian Marron, CEO of TxCell, how far they are in making autologous cellular therapy economically viable using their proprietary manufacturing process to produce patient specific therapies at a cost similar to other non personalised treatments?
TxCell is developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases. PharmaVentures' Adrian Dawkes asks Damian Marron, CEO of TxCell, how far they are in making autologous cellular therapy economically viable using their proprietary manufacturing process to produce patient specific therapies at a cost similar to other non personalised treatments?
Damian Marron
TxCell
TxCell
TxCell is developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases. TxCell's strategy is to target niche and orphan indications for which there are few or no treatment options. The product candidates developed by TxCell consist of autologous antigen-specific type 1 regulatory T cells (Ag-Tregs) generated ex-vivo from patient's blood in a proprietary manufacturing process (link). TxCell lead product candidate, OvasaveĀ®, has successfully completed a phase I/II clinical trial in Crohn's disease patients, refractory to all current treatments, with promising results (link). The next step in this program will be an international phase IIb clinical trial to confirm the positive phase I/II study results. Txcell second product candidate, Col-Treg, is in development for Autoimmune Uveitis, a rare disease with very limited treatment options. The next step in this program will be a phase I/II proof of principle clinical trial. Further product candidates for autoimmune inflammatory indications are in preclinical development.